Physician profile
Lynn Wang
NPI 1912929605
$12,429.67
in general payments reported to CMS, 2019-2025
61 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $1,281 · 2021: $1,432 · 2022: $1,817 · 2023: $1,409 · 2024: $3,361 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,615 · Travel and Lodging: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,615.46 |
| Travel and Lodging | $1,415.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,612.94 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,287.57 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Biogen, INC. | $878.48 | 2019-2025 | Vumerity, Skyclarys, Avonex |
| Abbvie INC. | $820.06 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lundbeck LLC | $551.33 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $426.24 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $404.43 | 2019-2024 | Austedo Xr, Austedo |
| Pfizer INC. | $328.14 | 2019-2025 | |
| Lilly USA, LLC | $321.24 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $294.51 | 2019-2024 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $275.58 | 2020-2024 | |
| Emd Serono, INC. | $274.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $272.83 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $242.89 | 2019-2024 | Rytary |
| Jazz Pharmaceuticals INC. | $218.00 | 2022-2025 | Epidiolex |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.